18F-FDG PET脑代谢模式与肌萎缩侧索硬化临床异质性及预后的关联:遗传与转录组视角
该前瞻性研究纳入127例ALS患者和128例年龄性别匹配健康对照,行脑18F-FDG PET/CT及临床评估。患者呈现额-纹状体-边缘网络低代谢与高代谢共存模式,高代谢与更好运动认知表现及更低焦虑抑郁相关,右侧额下回岛盖部高代谢、认知障碍和疾病进展率为生存独立预测因素,遗传突变状态与区域代谢改变相关。
要点
- ALS患者脑代谢呈额-纹状体-边缘网络低代谢与高代谢共存。
- 额-纹状体-边缘环路高代谢与更好运动认知及更低焦虑抑郁相关。
- 右侧额下回岛盖部高代谢、认知障碍和疾病进展率独立预测生存。
核心结论
- ALS患者脑代谢异常反映代偿与退变过程的复杂交互,与临床症状和预后密切相关。
- 整合FDG-PET代谢谱与遗传及转录信息可能有助于理解疾病异质性并支持个体化预后评估。
研究设计与样本
- 前瞻性研究纳入127例ALS患者和128例年龄性别匹配健康对照,行脑18F-FDG PET/CT。
- 临床评估包括运动功能、认知、焦虑和抑郁的标准化评价,采用线性回归分析代谢与临床变量关联,Cox比例风险模型评估生存结局。
- 进行全外显子组测序评估基因突变状态与突变负荷,并开展神经影像-转录组关联分析连接区域代谢改变与空间基因表达模式。
主要发现
- 与健康对照相比,ALS患者呈现额-纹状体-边缘网络内低代谢与高代谢共存的独特脑代谢模式。
- 视觉通路、颞叶和小脑可见显著低代谢(均p < 0.05)。
- 额-纹状体-边缘环路高代谢与更好运动认知表现及更低焦虑抑郁水平相关(均p < 0.05)。
- 多因素Cox回归确定右侧额下回岛盖部高代谢、认知障碍和疾病进展率为生存独立预测因素(均p < 0.05)。
- 基因突变状态和突变负荷与区域特异性代谢改变显著相关,神经影像-转录组分析揭示高代谢与低代谢脑区不同的转录特征。
临床怎么用
- 脑18F-FDG PET代谢模式可用于辅助评估ALS患者临床异质性及预后分层。
- 额-纹状体-边缘环路高代谢提示较好运动认知状态及较低情绪症状负担。
- 右侧额下回岛盖部高代谢结合认知障碍和疾病进展率有助于个体化生存预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive degeneration of upper and lower motor neurons. However, the neurobiological basis of disease heterogeneity and its prognostic relevance remain incompletely understood. METHODS: In this prospective study, 127 patients with ALS and 128 age- and sex-matched healthy controls underwent brain fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). Clinical assessments included standardized evaluations of motor function, cognition, anxiety, and depression. Associations between regional cerebral metabolism and clinical variables were examined using linear regression, whereas survival outcomes were evaluated with Cox proportional hazards models. Whole-exome sequencing was performed to assess genetic mutation status and mutation burden, and a neuroimaging-transcriptomic association analysis was conducted to link regional metabolic alterations with spatial gene expression patterns. RESULTS: Compared with the healthy controls, patients with ALS exhibited a distinctive cerebral metabolic pattern characterized by coexisting hypometabolism and hypermetabolism within the fronto-striatal-limbic network. Significant hypometabolism was observed in the visual pathways, temporal lobes, and cerebellum (all p < 0.05). Hypermetabolism within the fronto-striatal-limbic circuit was associated with better motor and cognitive performance, and lower levels of anxiety and depression (all p < 0.05). Multivariate Cox regression identified hypermetabolism in the right inferior frontal gyrus (opercular part), cognitive impairment, and disease progression rate as independent predictors of survival (all p < 0.05). In addition, genetic mutation status and mutation burden were significantly associated with region-specific metabolic alterations, and neuroimaging-transcriptomic analysis revealed distinct transcriptional signatures underlying hypermetabolic and hypometabolic brain regions. CONCLUSION: Cerebral metabolic abnormalities in patients with ALS reflected a complex interplay between compensatory and degenerative processes, which were closely linked to clinical symptoms and prognosis. Integrating FDG-PET metabolic profiles with genetic and transcriptional information may improve understanding of disease heterogeneity and support personalized prognostic assessment for patients with ALS. CLINICAL TRIAL REGISTRATION: Clinical trial number: not applicable.
引用
- Wang X, Wu F, Zhang J, et al. Cerebral metabolic patterns on 18F-FDG PET are associated with clinical heterogeneity and prognosis in amyotrophic lateral sclerosis: a genetic and transcriptomic perspective. Eur J Nucl Med Mol Imaging. 2026. PMID: 41989583. doi:10.1007/s00259-026-07871-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。